Searched for
BARICITINIB TABLETS
Study reveals arthritis drug can suppress progression of type 1 diabetesThe drug was found to safely preserve the body's insulin production and suppress the advancement of type 1 diabetes when initiated within 1...- First drug to treat hair loss disorder alopecia gets FDA approvalU.S. FDA has approved Eli Lilly's drug, Olumiant, which is considered the first to treat severe hair loss.
- Local firms got voluntary license for more drugs during pandemicA voluntary licence (VL) is an authorisation given by the patent holder to a generic company to produce a patented drug while a compulsory ...
- Mankind Pharma inks distribution pact with BDR Pharmaceuticals for COVID drugUnder the alliance, BDR Pharma will be manufacturing and marketing the product under a royalty free, limited and non-exclusive voluntary li...
- 18,040 oxygen concentrators, 7.7 lakh remdesivir vials received as foreign aid sent to statesCumulatively, 18,040 oxygen concentrators, 19,085 oxygen cylinders, 19 oxygen generation plants, 15,256 ventilators and BiPAP, around 7.7 l...
- MSN Labs launches black fungus drug Posaconazole in IndiaMSN Labs had earlier launched a Covid treatment portfolio of Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg, Oselow (Osel...
- Eli Lilly buckles under pressure, offers voluntary licence to Natco PharmaLily has issued voluntary licenses for Barcitinib to six Indian drug makers besides Natco, these include- Sun Pharma, Cipla, Dr Reddy's, Lu...
- Eli Lilly inks pacts for Baricitinib with Sun Pharma, Cipla, Lupin for COVID-19 treatment in IndiaAs the threat of compulsory licence (CL) looms over big pharma in India, companies are rushing in to sign voluntary licensing agreements th...
- Covid drug: Natco eyes patent waiverIn its application, Natco has cited the unmet medical needs due to the lack of supply and affordability in light of the grave and life-thre...
- Covid drug: Natco eyes patent waiverMaking its case, Natco’s application said Olumiant is not manufactured in India — less than 9,000 tablets were imported in 2019 and 2020, a...
- Natco gets emergency use nod for Baricitinib to treat Covid without trialsIn a statement, the Hyderabad headquartered pharma company said Baricitinib in combination with Remdesivir is used for the treatment of Cov...
- Natco Seeks emergency approval to launch Molnupiravir for Covid-19 in IndiaMolnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...
- SEC denies emergency nod to Natco Covid-19 drugNatco had in December sought a waiver of the clinical trial requirement for the emergency use of baricitinib tablets in Covid-19 treatment,...
- Hyderabad-based Natco Pharma wants to make Eli Lilly’s Covid drugNatco has sought nod for the manufacture and marketing of baricitinib bulk drug and tablets in 1 to 4 mg versions in India. This move may t...
Load More
